Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Other Infectious Diseases
Interventions: Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-Operative Pain
Interventions: Continuous Nerve Block; Procedure
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bipolar Disorder, Depressive Disorder
Interventions: buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteopenia
Interventions: AlgaeCal-1, AlgaeCal-2; Dietary Supplement
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Snake Bite
Interventions: Crotalinae (pit viper) equine immune F(ab)2, Crotalidae Polyvalent Immune Fab, ovine; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 10 more

Conditions: Depression
Interventions: Racemic ketamine, Spravato (Esketamine); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more

Conditions: Head Lice
Interventions: X92001327, RID shampoo; Other
Lead sponsor: Oystershell NV; Industry
Eligibility: 1 Year and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Blepharitis
Interventions: Erythromycin, Besifloxocin; Drug
Lead sponsor: John, George, M.D.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cervical Radiculopathy
Interventions: Gabapentin and/or Nortriptyline, Physical therapy, Epidural Steroid Injections (ESI), Combination treatment; Other · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Head Injury Trauma, Traumatic Brain Injury, Mild
Interventions: Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Sylmar, California • Torrance, California • Clinton Township, Michigan + 2 more

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 96
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more

Conditions: Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions: ZTI-01, Piperacillin-tazobactam; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more

Conditions: Acute Otitis Externa
Interventions: Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension; Drug
Lead sponsor: Exela Pharma Sciences, LLC.; Industry
Eligibility: 6 Months and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: NXL103, Linezolid; Drug
Lead sponsor: Novexel Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Chula Vista, California • Fountain Valley, California • La Mesa, California + 7 more

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Benzodiazepine Refractory Status Epilepticus
Interventions: Fosphenytoin, Levetiracetam, Valproic acid; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 2 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 65
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more

Conditions: Opioid-Related Disorders, NAS, Substance Use Disorders, Mental Health
Interventions: Observational Study; Other
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 2,510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Augusta, Maine • Bangor, Maine • Keene, New Hampshire + 6 more

Conditions: Multiple Sclerosis
Interventions: Exercise program for people with MS; Behavioral
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Athens, Georgia + 5 more

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Antimicrobial agent; Drug
Lead sponsor: Lakewood-Amedex Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Doral, Florida • Margate, Florida + 3 more

Conditions: Chronic Low Back Pain
Interventions: Buprenorphine transdermal delivery system; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999
U.S. locations: 22
States / cities: Huntsville, Alabama • Phoenix, Arizona • Waterbury, Connecticut + 19 more

Conditions: Traumatic Brain Injury
Interventions: levetiracetam, lacosamide; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Puberty, Precocious
Interventions: Bicalutamide, Anastrozole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 13 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more

Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions: Percutaneous Coronary Intervention (PCI); Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more

Conditions: Complicated Intra-Abdominal Infection
Interventions: CAZ-AVI, Metronidazole, Meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more

Search by objective public record fields.

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

Comparison of Pulmonary Function and Efficacy of Different Nerve Block Catheters for Shoulder Surgery

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

A Comparison of Changes in Bone Density With the Same Bone-health Plan, But With Different Bone-health Supplements

Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Conservative Therapy Versus Epidural Steroids for Cervical Radiculopathy

The PIONEER Comparative Effectiveness Study - Project 2

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Established Status Epilepticus Treatment Trial

MOms in REcovery (MORE) Study: Defining Optimal Care

Comparative Effectiveness Study Telerehab Versus Conventional

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections